Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin...
Leadership
William Chou M.D.
President, CEO & Director
Kathleen Borthwick
Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer
